Niagen Bioscience (NAGE) Interest Coverage Ratio (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Interest Coverage Ratio of 3.74 for Q1 2026, up 216.14% year-over-year from 1.18 in Q1 2025, and up 158.27% quarter-over-quarter from 6.42 in Q4 2025.
Niagen Bioscience (NAGE) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Interest Coverage Ratio for 17 consecutive years, with 3.74 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 216.14% year-over-year to 3.74; the TTM figure through Mar 2026 stood at 31.08 (up 846.68% YoY), while the FY2025 annual figure was 0.4, up 130.47% from the prior year.
- Interest Coverage Ratio improved to 3.74 in Q1 2026 per NAGE's latest filing, from 6.42 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 29.38 in Q4 2024 and bottomed at 15.53 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 0.13 across 5 years, with a median of 0.52 in 2023.
- On a YoY basis, Interest Coverage Ratio climbed as much as 1884.05% in 2024 and fell as far as 256.16% in 2024.
- Niagen Bioscience's Interest Coverage Ratio stood at 10.7 in 2022, then jumped by 84.6% to 1.65 in 2023, then jumped by 1884.05% to 29.38 in 2024, then slumped by 121.86% to 6.42 in 2025, then jumped by 158.27% to 3.74 in 2026.
- Business Quant data shows NAGE's Interest Coverage Ratio at 3.74 in Q1 2026, 6.42 in Q4 2025, and 6.45 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 0.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.27 |
| Mar 31, 2026 | 3.74 |
| Dec 31, 2025 | -6.42 |
| Sep 30, 2025 | 6.45 |
| Jun 30, 2025 | 0.82 |
| Mar 31, 2025 | 1.18 |
| Dec 31, 2024 | 29.38 |
| Sep 30, 2024 | 0.51 |
| Jun 30, 2024 | -1.04 |
| Mar 31, 2024 | -1.49 |
| Dec 31, 2023 | -1.65 |
| Sep 30, 2023 | -0.27 |
| Jun 30, 2023 | -0.52 |
| Mar 31, 2023 | -0.42 |
| Dec 31, 2022 | -10.70 |
| Sep 30, 2022 | -0.61 |
| Jun 30, 2022 | -1.21 |
| Mar 31, 2022 | -15.53 |
| Dec 31, 2021 | 11.29 |
| Sep 30, 2021 | -10.58 |